These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 5486044)

  • 1. [Treatment of hyperlipemia with a new lipid decreasing drug (Ciba 13,437-Su)].
    Hede S; Ditzel J; Dyerberg J
    Nord Med; 1970 Nov; 84(48):1539. PubMed ID: 5486044
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical evaluation of a new drug (CH 13437) in the treatment of hyperlipemia].
    Arteaga A; Foradori A; Eyzaguirre J; Lira P; Vasquez A; Soto S; Alliende ME; Guzman L
    Rev Med Chil; 1970 Oct; 98(10):689-94. PubMed ID: 4927028
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic effect of Ciba 13437-Su in 40 patients with familial essential hyperlipemia].
    Schönbeck M; Forster G; Hirzel H; Jakab T; Rosenmund H
    Dtsch Med Wochenschr; 1970 Aug; 95(35):1761-8. PubMed ID: 5451984
    [No Abstract]   [Full Text] [Related]  

  • 4. Preliminary evaluation of the hypolipidemic effects in man of a new phenolic ether (Su-13437, CIBA).
    Best MM; Duncan CH
    J Atheroscler Res; 1969; 10(1):103-6. PubMed ID: 5380895
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug treatment of hyperlipidemia.
    Berkowitz D
    Mod Treat; 1969 Nov; 6(6):1341-51. PubMed ID: 5377637
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug therapy. VI. Therapy of hyperlipidemias.
    Holcenberg JS; Hazzard WR
    Northwest Med; 1970 Jul; 69(7):503-5. PubMed ID: 5469352
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative hypolipidaemic effectiveness of gum guggulu (Commiphora mukul) fraction 'A', ethyl-P-chlorophenoxyisobutyrate and Ciba-13437-Su.
    Malhotra SC; Ahuja MM
    Indian J Med Res; 1971 Oct; 59(10):1621-32. PubMed ID: 5159000
    [No Abstract]   [Full Text] [Related]  

  • 8. Warfarin metabolism during ethyl chlorophenoxyisobutyrate treatment.
    Pyörälä K; Ristola P; Myllylä G
    Ann Med Intern Fenn; 1968; 57(4):157-60. PubMed ID: 5731345
    [No Abstract]   [Full Text] [Related]  

  • 9. [Some new drugs with the action on hyperlipidemia].
    Medaković M
    Med Pregl; 1968; 21(3):157-64. PubMed ID: 5192152
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential hypolipidemic agents. XVII. Synthesis and plasma lipid-lowering properties of compounds related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate and ethyl 2-(4-chlorophenoxy)-2-methylpropionate.
    Högberg T; Bondesson G; Stjernström NE
    Acta Pharm Suec; 1977; 14(2):149-60. PubMed ID: 906832
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hepatotoxic effects of 2-methyl-2-(p-(1,2,3,4-tetrahydro-1-naphthyl)-phenoxy)propionic acid (Ciba 13,437-Su)].
    Kattermann R; Arnold R; Creutzfeldt W
    Arzneimittelforschung; 1972 Mar; 22(3):616-9. PubMed ID: 4624899
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug therapy of the hyperlipidemias.
    Armstrong ML
    Iowa Med; 1985 Jan; 75(1):26-30. PubMed ID: 3967963
    [No Abstract]   [Full Text] [Related]  

  • 13. [Lipid-lowering drugs].
    Fortschr Med Suppl; 1988; 46():13-4. PubMed ID: 2905325
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect on serum tocopherol levels of drug-induced decrease in serum lipids.
    Weiss P; Bianchine JR
    Am J Med Sci; 1969 Oct; 258(4):275-81. PubMed ID: 5823464
    [No Abstract]   [Full Text] [Related]  

  • 15. [MPPG complex belongs in the first phase of drug-assisted lipid lowering (magnesium-pyridoxal-phosphate-glutamate )].
    Wieland H
    Fortschr Med; 1990; 108 Spec No 1():52-3. PubMed ID: 2245961
    [No Abstract]   [Full Text] [Related]  

  • 16. [Management of hyperlipemia. When to administer agents that regulate lipid disorders?].
    Cybulska B
    Kardiol Pol; 1991; 35(8):107-15. PubMed ID: 1942755
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of essential hyperlipemia with clofibrate].
    Reuter W; Seifert A
    Z Gesamte Inn Med; 1969 Jun; 24(12):184-7. PubMed ID: 5404292
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cost-benefit analysis of the therapy of lipid metabolism disorders].
    Karádi I
    Orv Hetil; 1996 May; 137(21):1164. PubMed ID: 8757110
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficacy of procetofen (lipanthyl) in hyperlipidemias (author's transl)].
    Stähelin HB; Seiler W; Pult N
    Schweiz Rundsch Med Prax; 1979 Jan; 68(1):24-8. PubMed ID: 760103
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacologic treatment of dyslipidemia.
    McCormick JJ; Deeg MA
    Am J Nurs; 2000 Feb; 100(2):55-60. PubMed ID: 10683645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.